Physician profile
Natalya Csatari
NPI 1366086894
$4,537.12
in general payments reported to CMS, 2019-2025
16 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $593 · 2023: $1,609 · 2024: $983 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,547 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.17 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,753.56 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $802.83 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $404.22 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $343.13 | 2022-2025 | Rexulti, Abilify Mycite |
| Alkermes, INC. | $283.21 | 2022-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $279.17 | 2022-2025 | Spravato |
| Axsome Therapeutics, INC. | $225.91 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $185.66 | 2025 | Fanapt |
| Lundbeck LLC | $73.80 | 2022-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $58.92 | 2022-2024 | Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $35.29 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $29.67 | 2025 | Jornay Pm |
| Corium, LLC | $16.09 | 2023 | Azstarys |
| Owp Pharmaceuticals, INC. | $16.08 | 2023 | Lamotrigine, Subvenite |
| Neurocrine Biosciences, INC. | $15.00 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalya Csatari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.